Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway

Annals of Neurology

Volumn 69, Issue 2, 2011, Pages 360-374

  Wang, Pei ^a   Xu, Tian Ying ^a   Guan, Yun Feng ^a   Tian, Wei Wei ^a   Viollet, Benoit ^b   Rui, Yao Cheng ^a   Zhai, Qi Wei ^c   Su, Ding Feng ^a   Miao, Chao Yu ^a,d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUT COCHIN   (France)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; DAPORINAD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA2; LENTIVIRUS VECTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN KINASE LKB1; SIRTUIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN TISSUE; CELL SURVIVAL; CONTROLLED STUDY; DEACETYLATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE SILENCING; GENETIC MANIPULATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN ISCHEMIA; CELLS, CULTURED; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NEURONS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SIRTUIN 1; STROKE; UP-REGULATION;

EID: 79952537492     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22236     Document Type: Article

References (31)

1. Donnan GA, Fisher M, Macleod M, Davis SM., Stroke. Lancet 2008; 371: 1612-1623. (Pubitemid 351626845)
2. Cushman M, Cantrell RA, McClure LA, et al. Estimated 10-year stroke risk by region and race in the United States: geographic and racial differences in stroke risk. Ann Neurol 2008; 64: 507-513.
3. Lo EH, Dalkara T, Moskowitz MA., Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399-415. (Pubitemid 37280178)
4. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunology 2002; 32: 3225-3234. (Pubitemid 35414880)
5. van der Veer E, Nong Z, O'Neil C, et al. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 2005; 97: 25-34. (Pubitemid 40982319)
6. Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375. (Pubitemid 350011996)
7. Wang P, Xu TY, Guan YF, et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81: 370-380.
8. Revollo JR, Grimm AA, Imai S., The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754-50763. (Pubitemid 40017813)
9. van der Veer E, Ho C, O'Neil C, et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 2007; 282: 10841-10845. (Pubitemid 47100731)
10. Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095-1107. (Pubitemid 47410271)
11. Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365. (Pubitemid 351556097)
12. Viollet B, Andreelli F, Jorgensen SB, et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003; 111: 91-98. (Pubitemid 36134852)
13. McBurney MW, Yang X, Jardine K, et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol 2003; 23: 38-54. (Pubitemid 36008499)
14. Tamatani M, Matsuyama T, Yamaguchi A, et al. ORP150 protects against hypoxia/ischemia-induced neuronal death. Nat Med 2001; 7: 317-323. (Pubitemid 32224347)
15. Puyal J, Vaslin A, Mottier V, Clarke PG., Postischemic treatment of neonatal cerebral ischemia should target autophagy. Ann Neurol 2009; 66: 378-389.
16. Vaslin A, Puyal J, Clarke PG., Excitotoxicity-induced endocytosis confers drug targeting in cerebral ischemia. AnnNeurol 2009; 65: 337-347.
17. Luo Y, Kuo CC, Shen H, et al. Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann Neurol 2009; 65: 520-530.
18. Lan F, Cacicedo JM, Ruderman N, Ido Y., SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1: possible role in AMP-activated protein kinase activation. J Biol Chem 2008; 283: 27628-27635.
19. Fombonne J, Rabizadeh S, Banwait S, et al. Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction. Ann Neurol 2009; 65: 294-303.
20. Gesuete R, Storini C, Fantin A, et al. Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol 2009; 66: 332-342.
21. Muruganandham M, Alfieri AA, Matei C, et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 2005; 11: 3503-3513. (Pubitemid 40627905)
22. Hardie DG., AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8: 774-785. (Pubitemid 47462132)
23. Li Y, Zhang Y, Dorweiler B, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 2008; 283: 34833-34843.
24. Turnley AM, Stapleton D, Mann RJ, et al. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J Neurochem 1999; 72: 1707-1716. (Pubitemid 29140848)
25. Vinet J, Carra S, Blom JM, et al. Cloning of mouse Ca2+/calmodulin- dependent protein kinase kinase beta (CaMKKbeta) and characterization of CaMKKbeta and CaMKKalpha distribution in the adult mouse brain. Brain Res Mol Brain Res 2003; 111: 216-221. (Pubitemid 36332346)
26. Alano CC, Garnier P, Ying W, et al. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 2010; 30: 2967-2978.
27. Wang S, Xing Z, Vosler PS, et al. Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair. Stroke 2008; 39: 2587-2595.
28. Pillai JB, Isbatan A, Imai S, Gupta MP., Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 2005; 280: 43121-43130. (Pubitemid 43049278)
29. Fulco M, Cen Y, Zhao P, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 2008; 14: 661-673. (Pubitemid 351622608)
30. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-1060.
31. Avalos JL, Bever KM, Wolberger C., Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 2005; 17: 855-868. (Pubitemid 40386946)